Taiwan · Delayed Price · Currency is TWD Lumosa Therapeutics Company Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia.
The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors.
In addition, the company engages in the investment, new drug development consulting, and service and transfer of techniques activities.
The company was formerly known as SunTen Phytotech Co., Ltd. and changed its name to Lumosa Therapeutics Co., Ltd. in June 2014.
Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Sheng Wen Yeh |
Contact Details
Address: No. 3-2, Park Street Taipei, 11503 Taiwan | |
| Phone | 886 2 2655 7918 |
| Website | lumosa.com.tw |
Stock Details
| Ticker Symbol | 6535 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006535008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sheng Wen Yeh | General Manager |
| Li Fang Pan | Chief Financial Officer and Manager of the Administrative Office |
| Pei-Jiun Chen | Chief Operating Officer |
| Lan Ying Huang | Accounting Supervisor |